Wednesday, January 18, 2012

FDA Approves Glucarpidase to Reduce Toxic Levels of Methotrexate

"The FDA has approved glucarpidase (marketed as Voraxaze) to lower toxic levels of methotrexate related to kidney failure. Cancer patients may develop kidney failure when treated with high doses of methotrexate. In a study of 22 patients receiving glucarpidase, 10 patients had methotrexate levels fall below a critical level within 15 minutes and stay low for 8 days. The drug eliminated 95% of methotrexate in all patients."

This should be a resourceful drug for our patients; especially those who receive intrathecall/IV MTX and get kidney injury where we often have to do dialysis due to the toxic levels; so potentially saving patients from dialysis and it's complications.

No comments:

Post a Comment

All Posts

Search This Blog